Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Xeris Biopharma to Report First Quarter 2023 Financial Results on May 9, 2023 Business Wire - Tue May 2, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.08 (+0.97%)
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations Business Wire - Tue Apr 18, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.08 (+0.97%)
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™ Business Wire - Thu Mar 30, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...

XERS : 2.08 (+0.97%)
Xeris Biopharma Appoints Ricki Fairley to Board of Directors Business Wire - Wed Mar 29, 2023

Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic...

XERS : 2.08 (+0.97%)
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance Business Wire - Wed Mar 8, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.08 (+0.97%)
Xeris Biopharma to Report Fourth Quarter and Full-Year 2022 Financial Results on March 8, 2023 Business Wire - Thu Feb 23, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.08 (+0.97%)
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023 Business Wire - Thu Feb 2, 2023

Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 2.08 (+0.97%)
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev® Business Wire - Mon Jan 30, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies,...

XERS : 2.08 (+0.97%)
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference Business Wire - Thu Jan 5, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.08 (+0.97%)
Xeris Biopharma Updates Its Outlook For 2022 Business Wire - Thu Jan 5, 2023

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range...

XERS : 2.08 (+0.97%)

Barchart Exclusives

Large Unusual Activity in Tesla Put Options Dominates the Options Market Today Barchart - 27 minutes ago
Today there is large, unusual activity in Tesla options. This is almost certainly due to the recent rise in TSLA stock. The puts highlight investors' concerns about Tesla stock, but they also present good income plays. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot